NCT01709929View on ClinicalTrials.gov

Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL

Enrollment

2,287

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Interventions

DRUG

insulin detemir

Administered subcutaneously (s.c., under the skin). Dose individually adjusted.

Trial Locations (1)

L4W 4XI

Mississauga

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY